38
Participants
Start Date
October 31, 2025
Primary Completion Date
October 31, 2028
Study Completion Date
April 30, 2033
Pembrolizumab
Given intravenously
Non-investigational, involved site radiotherapy (ISRT)
Undergo possible, standard of care, non-investigational radiation therapy
Gemcitabine
Given IV
Vinorelbine
Given IV
Liposomal Doxorubicin
Given IV
Foresight CLARITY™ LDT
Foresight CLARITY LDT, a laboratory-developed test (LDT),by Foresight Diagnostics, is an ultra-sensitive liquid biopsy and tissue platform that detects MRD in patients with B-cell lymphomas
Pegfilgrastim
Given IV for supportive care
Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)
Undergo imaging
Unversity of California, Los Angeles, Los Angeles
University of California, San Diego, La Jolla
University of California Irvine, Irvine
University of California San Francisco-Fresno, Fresno
University of California, San Francisco, San Francisco
University of California Davis, Davis
Collaborators (1)
UC Hematologic Malignancies Consortium (UCHMC)
UNKNOWN
Foresight Diagnostics
UNKNOWN
Gateway for Cancer Research
OTHER
Michael Spinner, MD
OTHER